Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) and Talphera (NASDAQ:TLPH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.
Profitability
This table compares Inhibikase Therapeutics and Talphera’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibikase Therapeutics | N/A | -42.80% | -40.58% |
| Talphera | N/A | -87.28% | -51.36% |
Institutional & Insider Ownership
3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibikase Therapeutics | $260,000.00 | 1,043.87 | -$48.26 million | ($0.43) | -4.52 |
| Talphera | $30,000.00 | 1,939.70 | -$14.29 million | ($0.27) | -4.15 |
Talphera has lower revenue, but higher earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Inhibikase Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Inhibikase Therapeutics and Talphera, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibikase Therapeutics | 1 | 1 | 4 | 3 | 3.00 |
| Talphera | 1 | 1 | 2 | 0 | 2.25 |
Inhibikase Therapeutics presently has a consensus target price of $5.40, suggesting a potential upside of 177.63%. Talphera has a consensus target price of $3.00, suggesting a potential upside of 167.62%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Inhibikase Therapeutics is more favorable than Talphera.
Summary
Inhibikase Therapeutics beats Talphera on 9 of the 14 factors compared between the two stocks.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
